Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00678392 · ClinicalTrials.gov registry record · Phase 3
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 723
- Enrollment target
NCT00678392 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 723 participants.
The verdict
NCT00678392, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 723 participants
- Enrollment target
Study Summary
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
Interventions
- DRUG Sorafenib
- DRUG Axitinib (AG-013736)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 723 participants |
| Start Date | 2008-09-03 |
| Est. Completion | 2016-02-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00678392
The ClinicalTrials.gov registry entry for NCT00678392 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 723 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT00678392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00678392 about?
NCT00678392 is a clinical study titled "Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer". The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
What is the current status of trial NCT00678392?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 723 participants. The study started on 2008-09-03. Estimated completion is 2016-02-25.
What interventions are being tested in trial NCT00678392?
The interventions under investigation include: Sorafenib (DRUG), Axitinib (AG-013736) (DRUG).
Who is sponsoring clinical trial NCT00678392?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.